Ru­bius marks mile­stone in PhI/II as CFO de­parts; Owkin clos­es $70M Se­ries A; The Car­lyle Group bets on In­di­an CD­MO

→ Some of the folks at Ru­bius Ther­a­peu­tics weren’t too keen about our lede on the Take­da gene ther­a­py sto­ry, which ref­er­enced their R&D mishaps. So they flagged an­oth­er re­lease out this morn­ing, which high­lights that the biotech has “com­plet­ed dos­ing of the first dose-es­ca­la­tion co­hort with no ob­served ad­verse events to date in the Phase 1/2 clin­i­cal tri­al of RTX-240.” On an­oth­er note, their CFO, An­drew Oh, is head­ed out the ex­it in a few months. They now have a search un­der­way for his suc­ces­sor as Oh stays on for a tran­si­tion pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER